A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease
Start Date
5/28/2025
Completion Date
9/1/2028
Summary
A study to determine if BHV-8000 is efficacious, safe and tolerable in adults diagnosed with early Parkinson's disease. The study will consist of a 48-week double-blind treatment phase followed by a 48-week open-label phase.
Eligibility Criteria
Age Range: 40 years to 80 years
Interventions
BHV-8000 10mg
BHV-8000 20 mg
Placebo
Conditions
Locations
Site-049
Birmingham, Alabama 35294
United States
Site-041
Los Angeles, California 90033
United States
Site-031
Farmington, Connecticut 06030
United States
Site-028
New Haven, Connecticut 06510
United States
Site-038
Atlantis, Florida 33462
United States
Site-017
Boca Raton, Florida 33486
United States
Site-051
Maitland, Florida 32751
United States
Site-027
Chicago, Illinois 60611
United States
Site-071
Boston, Massachusetts 02114
United States
Site-015
Farmington Hills, Michigan 48334
United States
Site-044
Chesterfield, Missouri 63005
United States
Site-005
New York, New York 10021
United States
Site-091
Portland, Oregon 97210
United States
Site-043
Round Rock, Texas 78681
United States
Site-007
Bellevue, Washington 98007
United States